跳转到主内容

非常抱歉,我们不完全支持您的浏览器。如果您可以选择,请升级到较新版本或使用 Mozilla Firefox、Microsoft Edge、Google Chrome 或 Safari 14 或更高版本。如果您无法进行此操作且需要支持,请将您的反馈发送给我们。

全新设计的官网为您带来全新体验,期待您的反馈 在新的选项卡/窗口中打开

Elsevier
通过我们出版

Dr. V. Craig Jordan

DVCJ

Dr. V. Craig Jordan

Author profile 在新的选项卡/窗口中打开

Professor of Breast Medical Oncology, Professor of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, TX. Previously, he was Chief Scientific Officer and Vice President of Oncology at Georgetown University's Lombardi Comprehensive Cancer Center. Jordan was the first to discover the breast cancer prevention properties of tamoxifen and the scientific principles for adjuvant antihormone therapy. More recently, his work has branched out into the prevention of multiple diseases in women with the discovery of the selective estrogen receptor modulator (SERM) group of drugs. Currently, she plans to develop a new Hormone Replacement Therapy (HRT) for postmenopausal women that prevents breast cancer and does not increase the risk of breast cancer. Affiliations and Experience Professor of Breast Medical Oncology, Professor of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.